Drug intelligence / Profile preview

NEO-5171

Development stage: Unknown
Lead developer: Neurogene
Modality: Recombinant Proteins and Enzymes

Overview

NEO-5171 is a de novo protein developed by Neoleukin Therapeutics. It is designed as an inhibitor of both Interleukin-2 (IL-2) and Interleukin-15 (IL-15) signaling. Neoleukin Therapeutics focused on creating next-generation immunotherapies for cancer, inflammation, and autoimmunity using sophisticated computational methods for de novo protein design.

Targets

IL2RB (IL-2 receptor beta chain)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on NEO-5171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-5171.

Explore the full profile